[IVOM quality assurance in Westfalen-Lippe : Structure of quality assurance and results of the pilot study Q-VERA].
Intravitreale operative Medikamenteneingabe (IVOM) – Qualitätssicherung in Westfalen-Lippe : Aufbau der Qualitätssicherung und Ergebnisse der Pilotstudie Q-VERA.
Age-related macular degeneration
Case management
Compliance
Electronic quality assurance
Treatment quality
Journal
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
ISSN: 1433-0423
Titre abrégé: Ophthalmologe
Pays: Germany
ID NLM: 9206148
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
pubmed:
9
1
2020
medline:
16
5
2020
entrez:
9
1
2020
Statut:
ppublish
Résumé
The KVWL-QS assists ophthalmologists in the transfer for good clinical praxis into real life. In addition the QS-commission initiated a pilotstudy "Qualitäts-Versorgung bei AMD" (Q‑VERA) in order to test new instruments for improvements. It was analized, if Reading Center (RC) based controls in combination with specific case-management modules can improve the results of IVOM treatment. In 5 treatment centers 878 consecutive patients with newly diagnosed AMD (Neu-Patienten) were included, who were treated with the IVAN-scheme. Initial FA and OCT images were transferred electronically to the RC. Also 781 retreatment patients (mean 20.7 IVOM before) with retreatment due to lesion activity were observed. In 5% of the 878 newly treated patients a discrepancy between RC and treatment center was recorded. In this group the 481 patients, who finished up to the analysis date the 12-month follow-up, the visual function (increase in BCVA) and SD-OCT (reduction in central retinal thickness) results were comparable with large prospective cohorts. This was achieved with 6.5 injections and 10.6 visits over 12 months. In the group of 781 patients with repeated injections the number of injections over 12 months was 7.7 and the number of visits 11.6. Quality assessment can improve the efficacy of IVOM therapy for AMD patients in real life. In addition to existing structures, electronical exchange by a RC assisted evaluation can further improve the quality by reducing the number of unnecessary treatment visits. The case-management with adherence control, re-call-system and specific information for patients and relatives can specifically increase the long-term adherence and thus the success of the therapy.
Sections du résumé
BACKGROUND
BACKGROUND
The KVWL-QS assists ophthalmologists in the transfer for good clinical praxis into real life. In addition the QS-commission initiated a pilotstudy "Qualitäts-Versorgung bei AMD" (Q‑VERA) in order to test new instruments for improvements. It was analized, if Reading Center (RC) based controls in combination with specific case-management modules can improve the results of IVOM treatment.
PATIENTS AND METHODS
METHODS
In 5 treatment centers 878 consecutive patients with newly diagnosed AMD (Neu-Patienten) were included, who were treated with the IVAN-scheme. Initial FA and OCT images were transferred electronically to the RC. Also 781 retreatment patients (mean 20.7 IVOM before) with retreatment due to lesion activity were observed.
RESULTS
RESULTS
In 5% of the 878 newly treated patients a discrepancy between RC and treatment center was recorded. In this group the 481 patients, who finished up to the analysis date the 12-month follow-up, the visual function (increase in BCVA) and SD-OCT (reduction in central retinal thickness) results were comparable with large prospective cohorts. This was achieved with 6.5 injections and 10.6 visits over 12 months. In the group of 781 patients with repeated injections the number of injections over 12 months was 7.7 and the number of visits 11.6.
CONCLUSION
CONCLUSIONS
Quality assessment can improve the efficacy of IVOM therapy for AMD patients in real life. In addition to existing structures, electronical exchange by a RC assisted evaluation can further improve the quality by reducing the number of unnecessary treatment visits. The case-management with adherence control, re-call-system and specific information for patients and relatives can specifically increase the long-term adherence and thus the success of the therapy.
Identifiants
pubmed: 31912271
doi: 10.1007/s00347-019-01030-3
pii: 10.1007/s00347-019-01030-3
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
336-342Références
Ophthalmologe. 2014 May;111(5):438-42
pubmed: 24838864
J Fr Ophtalmol. 2015 Sep;38(7):620-7
pubmed: 25913443
Br J Ophthalmol. 2017 Mar;101(3):353-359
pubmed: 27215744
Ophthalmologe. 2019 May;116(5):441-446
pubmed: 29923031
Acta Ophthalmol. 2013 Sep;91(6):540-6
pubmed: 23171290
Ophthalmologe. 2016 Jul;113(7):570-80
pubmed: 26868827
Ophthalmology. 2016 Aug;123(8):1751-1761
pubmed: 27156698
Ophthalmologe. 2015 Mar;112(3):246-54
pubmed: 25668709
Ophthalmologe. 2016 Nov;113(11):925-932
pubmed: 27272633
Br J Ophthalmol. 2015 Feb;99(2):220-6
pubmed: 25193672
Ophthalmology. 2016 Apr;123(4):876-83
pubmed: 26778346
Ophthalmologe. 2018 Dec;115(12):1035-1041
pubmed: 29138977
Ophthalmologe. 2019 Aug;116(8):753-765
pubmed: 30367231
Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):647-55
pubmed: 24424409
Graefes Arch Clin Exp Ophthalmol. 2017 Nov;255(11):2237-2246
pubmed: 28776095
Ophthalmologe. 2020 Jun;117(6):557-565
pubmed: 31555836
Lancet. 2013 Oct 12;382(9900):1258-67
pubmed: 23870813
Retina. 2018 Jun;38(6):1134-1144
pubmed: 28489692
Ophthalmologe. 2015 Mar;112(3):237-45
pubmed: 25739373
Klin Monbl Augenheilkd. 2015 Feb;232(2):202-10
pubmed: 25700258
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4324-31
pubmed: 26176869